The Need for New Surrogate Markers for Immune Monitoring and Efficacy Assessment
Tags: Drug Development, Immune Monitoring, Immunogenicity, Surrogate Markers of Efficacy, Vaccine Development
It is of concern of all in pharma and biotech research fields that the number of vaccines and drugs that get to the market is very low compared to the number that enter phase I clinical trial testing. For this to change, among other improvements, new surrogate markers must be identified early on for the purpose of patient stratification, immune monitoring and/or therapeutic or prophylactic efficacy assessment.
